CSPG4 and neoplasm: Somatic mutation in the CSPG4 gene was significantly associated with PD-L1 positivity (predictor of the response to immunotherapy with PD-1/PD-L1 inhibitors) in renal cell carcinoma tumor cells in a study by Wang et al. [27].